A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma

E-ISSN： 1875-6913|12|4|188-198

ISSN： 1875-6921

Source： Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol.12, Iss.4, 2014-12, pp. : 188-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma

Current Clinical Pharmacology, Vol. 10, Iss. 4, 2015-10 ,pp. : 256-266

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Metastatic Pancreatic Cancer

By Ko Andrew H. Tempero Margaret A.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 3, Iss. 5, 2005-09 ,pp. : 627-636

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Flutamide in unresectable pancreatic adenocarcinoma: A randomized, double-blind, placebo-controlled trial

By Negi Sanjay Agarwal Anil Chaudhary Adarsh

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 189-194

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel is active in patients with unresectable metastatic or locally advanced pancreatic cancer

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Metastatic Colorectal Cancer: Current Systemic Treatment Options

By Board Ruth E. Valle Juan W.

Drugs, Vol. 67, Iss. 13, 2007-01 ,pp. : 1851-1867

Adis International

Access to resources Recommend Favorite